Literature DB >> 23524406

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Charles M Rudin1, Kelvin Hong, Michael Streit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23524406      PMCID： PMC3634121          DOI： 10.1097/JTO.0b013e31828bb1b3

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Resistance to BRAF-targeted therapy in melanoma.

Authors:  Ryan J Sullivan; Keith T Flaherty
Journal:  Eur J Cancer       Date:  2013-01-02       Impact factor: 9.162

2.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

Authors:  Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Authors:  Piro Lito; Christine A Pratilas; Eric W Joseph; Madhavi Tadi; Ensar Halilovic; Matthew Zubrowski; Alan Huang; Wai Lin Wong; Margaret K Callahan; Taha Merghoub; Jedd D Wolchok; Elisa de Stanchina; Sarat Chandarlapaty; Poulikos I Poulikakos; James A Fagin; Neal Rosen
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

4.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

5.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.

Authors:  Hongbin Ji; Zhenxiong Wang; Samanthi A Perera; Danan Li; Mei-Chih Liang; Sara Zaghlul; Kate McNamara; Liang Chen; Mitchell Albert; Yanping Sun; Ruqayyah Al-Hashem; Lucian R Chirieac; Robert Padera; Roderick T Bronson; Roman K Thomas; Levi A Garraway; Pasi A Jänne; Bruce E Johnson; Lynda Chin; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701
  5 in total
  27 in total

1.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

Review 2.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

Review 3.  Targeting BRAF mutations in non-small cell lung cancer.

Authors:  Connor Gerard O'Leary; Vladamir Andelkovic; Rahul Ladwa; Nick Pavlakis; Caicun Zhou; Fred Hirsch; Derek Richard; Kenneth O'Byrne
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Authors:  J B Auliac; S Bayle; A Vergnenegre; H Le Caer; L Falchero; R Gervais; H Doubre; F Vinas; B Marin; C Chouaid
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

5.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Authors:  David Planchard; Tae Min Kim; Julien Mazieres; Elisabeth Quoix; Gregory Riely; Fabrice Barlesi; Pierre-Jean Souquet; Egbert F Smit; Harry J M Groen; Ronan J Kelly; B C Cho; Mark A Socinski; Lini Pandite; Christine Nase; Bo Ma; Anthony D'Amelio; Bijoyesh Mookerjee; C Martin Curtis; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2016-04-11       Impact factor: 41.316

6.  Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Authors:  Stephanie Cardarella; Atsuko Ogino; Mizuki Nishino; Mohit Butaney; Jeanne Shen; Christine Lydon; Beow Y Yeap; Lynette M Sholl; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

Review 7.  Personalizing therapy in advanced non-small cell lung cancer.

Authors:  Liza C Villaruz; Timothy F Burns; Vasilis S Ramfidis; Mark A Socinski
Journal:  Semin Respir Crit Care Med       Date:  2013-11-20       Impact factor: 3.119

8.  Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Authors:  Ross A Okimoto; Luping Lin; Victor Olivas; Elton Chan; Evan Markegard; Andrey Rymar; Dana Neel; Xiao Chen; Golzar Hemmati; Gideon Bollag; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-09       Impact factor: 11.205

9.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 10.  Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Authors:  Catherine B Meador; Christine M Micheel; Mia A Levy; Christine M Lovly; Leora Horn; Jeremy L Warner; Douglas B Johnson; Zhongming Zhao; Ingrid A Anderson; Jeffrey A Sosman; Cindy L Vnencak-Jones; Kimberly B Dahlman; William Pao
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.